Effectiveness of novel PGM-containing incomplete Seppic adjuvants in rabbits

Vaccine

Volumn 25, Issue 17, 2007, Pages 3475-3481

  Halassy, Beata ^a   Vdović, Valerija ^a   Habjanec, Lidija ^a   Balija, Maja Lang ^a   Gebauer, Branka ^a   Sabioncello, Ante ^a   Šantek, Tomislav ^a   Tomašić, Jelka ^a  

^a INSTITUTE OF IMMUNOLOGY   (Croatia)

Author keywords

Adjuvants; Montanide ISA 206; Montanide ISA 720; Peptidoglycan monomer

Indexed keywords

ANTIBODY; DRUG CARRIER; FREUND ADJUVANT; IMMUNOGLOBULIN G; ISA 206; ISA 720; MONOMER; PEPTIDOGLYCAN; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DEGRADATION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG POTENCY; HEMAGGLUTINATION; IMMUNIZATION; MALE; METABOLIC CLEARANCE RATE; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; IMMUNOGLOBULIN G; MALE; MANNITOL; OLEIC ACIDS; OLIGODEOXYRIBONUCLEOTIDES; PEPTIDOGLYCAN; RABBITS;

EID: 34047243821     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.12.040     Document Type: Article

References (33)

1. Keglević D., Ladešić B., Hadžija O., Tomašić J., Valinger Z., Pokorny M., et al. Isolation and study of the composition of a peptidoglycan complex excreted by the biotin-requiring mutant of Brevibacterium divaricatum NRRL-2311 in the presence of penicillin. Eur J Biochem 42 (1974) 389-400
2. Keglević D., Ladešić B., Tomašić J., Valinger Z., and Naumski R. Isolation procedure and properties of monomer unit from lysozyme digest of peptidoglycan complex excreted into the medium by penicillin-treated Brevibacterium divaricatum mutant. Biochim Biophys Acta 585 (1979) 273-281
3. Tomašić J., Sesartić Lj, Martin S.A., Valinger Z., and Ladešić B. Comparative susceptibility of a peptidoglycan monomer from Brevibacterium divaricatum and its anhydromuramyl analogue to hydrolysis with N-acetylmuramyl-l-alanine amidase. J Chromatogr 440 (1988) 405-414
4. Matter H., Szilagyi L., Forgo P., Marinić Ž, and Klaić B. Structure and dynamics of a peptidoglycan monomer in aqueous solution using NMR spectroscopy and simulated annealing calculations. J Am Chem Soc 119 (1997) 2212-2223
5. Halassy B., Habjanec L., and Tomašić J. Peptidoglycan monomer-product of biotechnology with immunomodulatory properties. Immuno-modulatory drugs. Current studies of biotechnology vol. IV (2005), Croatian Society of Biotechnology and Medicinska Naklada, Zagreb pp. 137-43
6. Tomašić J., Hanzl-Dujmović I., Špoljar B., Vranešić B., Šantak M., and Jovičić A. Comparative study of the effects of peptidoglycan monomer and structurally related adamantyltripeptides on humoral immune response to ovalbumin in the mouse. Vaccine 18 (2000) 1236-1243
7. Ljevaković D., Tomašić J., Šporec V., Halassy Špoljar B., and Hanzl-Dujmović I. Synthesis of novel adamantylacetyl derivative of peptidoglycan monomer-biological evaluation of immunomodulatory peptidoglycan monomer and respective derivatives with lipophilic substituents on amino group. Bioorg Med Chem 8 (2000) 2441-2449
8. Halassy B., Krstanović M., Frkanec R., and Tomašić J. Adjuvant activity of peptidoglycan monomer and its metabolic products. Vaccine 21 (2003) 971-976
9. Halassy Špoljar B., Čimbora T., Hanzl-Dujmović I., Dojnović B., Sabioncello A., Krstanović M., et al. Influence of adjuvant-active peptidoglycan monomer on specific T cell responses in mice. Vaccine 20 (2002) 3543-3550
10. Halassy B., Mateljak S., Bouche F.F., Putz M.M., Muller C.P., Frkanec R., et al. Immunogenicity of peptides of measles virus origin and influence of adjuvants. Vaccine 24 (2006) 185-194
11. Lang Balija M, Immune reaction specific for venom of long-nosed viper (Vipera ammodytes) in mice and influence of adjuvants. Master of Science Thesis. Zagreb; 2002 (in Croatian).
12. Halassy Špoljar B, Adjuvant activity of peptidoglycan monomer in mice. Doctoral Thesis. Zagreb; 2003 (in Croatian).
13. Tomašić J., Ladešić B., Valinger Z., and Hršak I. The metabolic fate of 14C-labeled peptidoglycan monomer in mice. I. Identification of the monomer and the corresponding pentapeptide in urine. Biochim Biophys Acta 629 (1980) 77-82
14. 14C-labeled immunoadjuvant peptidoglycan monomer. II: In vitro studies. Biochim Biophys Acta 678 (1981) 12-17
15. Valinger Z., Ladešić B., and Tomašić J. Partial purification and characterisation of N-acetylmuramyl-l-alanine amidase from human and mouse serum. Biochim Biophys Acta 701 (1982) 63-71
16. Aucouturier J., Dupuis L., Deville S., Ascarateil S., and Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 1 (2002) 111-118
17. Cox S.J., Aggarwal N., Statham R.J., and Barnett P.V. Longevity of antibody and cytokine responses following vaccination with high potency emergency FMD vaccines. Vaccine 21 (2003) 1336-1347
18. Krstanović M., Frkanec R., Vranešić B., Ljevaković D., Šporec V., and Tomašić J. Reversed-phase high-performance liquid chromatographic method for the determination of peptidoglycan monomers and structurally related peptides and adamantyltripeptides. J Chromatogr B 773 (2002) 167-174
19. Leenars P.P.A.M., Hendriksen C.F.M., de Leeuw W.A., Carat F., Delahaut P., Fischer R., et al. The production of polyclonal antibodies in laboratory animals. The report and recommendations of ECVAM workshop 35. ATLA 27 (1999) 79-102
20. Wright S.P. Adjusted P-values for simultaneous inference. Biometrics 27 (1992) 77-81
21. Habjanec L., Frkanec R., Halassy B., and Tomašić J. Effect of liposomal formulations and immunostimulating peptidoglycan monomer (PGM) on the immune reaction to ovalbumin in mice. J Liposome Res 16 (2006) 1-16
22. Cox J.C., and Coulter A.R. Adjuvants-a classification and review of their modes of action. Vaccine 15 (1997) 248-256
23. Saul A., Lawrence G., Allworth A., Elliot S., Anderson K., Rzepczyk C., et al. A human phase I vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA 720 adjuvant. Vaccine 23 (2005) 3076-3083
24. Oliveira G.A., Wetzel K., Calvo-Calle M., Nussenzweig R., Schmidt A., Birkett A., et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 73 (2005) 3587-3597
25. Toledo H., Baly A., Castro O., Resik S., Laferté J., Rolo F., et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 19 (2001) 4328-4336
26. Lawrence G.W., Saul A., Giddy A.J., Kemp R., and Pye D. Phase I trial in humans of an oil-based adjuvant Seppic Montanide ISA 720. Vaccine 15 (1997) 176-178
27. Aucouturier J., Ascarateil S., and Dupuis L. The use of oil adjuvants in therapeutic vaccines. Vaccine 24 (2006) S44-S45
28. Stewart-Tull D. The future potential for the use of adjuvants in human vaccines. In: Hincal A.A., and Kas H.S. (Eds). Biomedical science and technology (1998), Plenum Press, New York 129-136
29. Jansen T., Hofmans M.P.M., Theelen M.J.G., Manders F., and Schijns V.E.J.C. Structure- and oil type-based efficacy of emulsion adjuvants. Vaccine 24 (2006) 5400-5405
30. Kirkley J.E., Goldstein A.L., and Naylor P.H. Adjuvant properties of Montanide CSA 720 with a recombinant HIV P17 gag protein and synthetic peptide antigens. Scand J Immunol 43 (1996) 431
31. 19) formulated in oil-based Montanides. Vaccine 21 (2003) 2923-2932
32. Ioannou X.P., Gomis S.M., Karvonen B., Hecker R., Babiuk L.A., and van Drunen Littel-van den Hurk S. CpG-containing oligodeoxynucleotides, in combination with conventional adjuvant, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21 (2002) 127-137
33. Johansson J., Ledin A., Vernersson M., Lövgren-Bengtsson K., and Hellman L. Identification of adjuvants that enhance the therapeutic antibody response to host IgE. Vaccine 22 (2004) 2873-2880